Eldecalcitol
- Generic Name
- Eldecalcitol
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C30H50O5
- CAS Number
- 104121-92-8
- Unique Ingredient Identifier
- I2JP8UE90H
- Background
Eldecalcitol (ED-71), a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Eldecalcitol, effectively and safely increased lumbar and hip bone mineral density (BMD) in osteoporotic patients who also received vitamin D3 supplementation.
- Indication
Investigated for use/treatment in osteoporosis.
- Associated Conditions
- -
- Associated Therapies
- -
Clinical Intervention of Idecalcitol Combined With Whey Protein Powder and Exercise for Sarcopenia
- Conditions
- Interventions
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Zhejiang Provincial People's Hospital
- Target Recruit Count
- 450
- Registration Number
- NCT06537115
- Locations
- 🇨🇳
The First People's Hospital of Chun'an County, Hangzhou, Zhejiang, China
🇨🇳Dinghai Central Hospital of Zhoushan City, Zhoushan, Zhejiang, China
🇨🇳Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
Comparison of Efficacy of Denosumab With Eldecalcitol or Native Vitamin D in Postmenopausal Women With Osteoporosis.
- Conditions
- Interventions
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Xi'an Honghui Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05884372
- Locations
- 🇨🇳
Zeng,Yuhong, Xi'an, China
Eldecalcitol for GLucocorticoid Induced OsteopoRosIs Versus Alfacalcidol
- First Posted Date
- 2013-11-01
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- e-GLORIA trial Protocol Review Committee
- Target Recruit Count
- 400
- Registration Number
- NCT01974167
- Locations
- 🇯🇵
Nara Hospital Kinki University Faculty of Medicine, Ikoma, Nara, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.